TSH

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024
ENDO, SAN, Congenital adrenal hyperplasia, Holocene, Carcinoid syndrome, Research, Entrepreneurship, Investment, FDA, Food, Webcast, Growth, Graves' ophthalmopathy, Primary hyperparathyroidism, PTH1R, Somatostatin, Conference, Endocrinology, Safety, TSH, Patient, CAH, Trial of the century, NDA, PHPT, Pharmaceutical industry

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ET Today
    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • We also expect full results from our Phase 2 study in carcinoid syndrome in the first half of this year.
  • In December 2023, Crinetics reported an initial analysis of data from a subset of 27 patients.
  • Earlier today, February 28, 2024, Crinetics announced a private placement equity financing for gross proceeds of approximately $350 million.

iClick Interactive Asia Group Limited Announces Shareholders' Approval of Merger Agreement

Retrieved on: 
Friday, March 8, 2024
The Company, ADS, Cayman Islands, Plan, Registrar, Marketing, Proxy, Cayman, TSH, EGM, Sub

Each shareholder has one vote for each Class A Share or 20 votes for each Class B Share.

Key Points: 
  • Each shareholder has one vote for each Class A Share or 20 votes for each Class B Share.
  • The Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger, were approved by approximately 99.77% of the total votes cast at the EGM.
  • The completion of the Merger is subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement.
  • The Company will work with the other parties to the Merger Agreement towards satisfying all other conditions precedent to the Merger set forth in the Merger Agreement and completing the Merger as quickly as possible.

What do your blood test results mean? A toxicologist explains the basics of how to interpret them

Retrieved on: 
Tuesday, February 6, 2024
Glycated hemoglobin, Thyroid, BMP, Physical examination, Disorder, Hypothyroidism, Cell, BUN, Immune system, History, RBC, Heart, Blood urea nitrogen, Diabetes, Biomarker, Blood, Patient, Kidney, Triiodothyronine, Temperature, HB, TSH, Anemia, Nutrient, A1C, Disease, Thyroid hormones, Brain, Hematocrit, Fatigue, Waste, Health, HCT, Hormone, Plasma, Woman, Medical imaging

As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.

Key Points: 
  • As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.
  • Understanding what common blood tests are intended to measure can help you better interpret the results.
  • If you have results from a recent blood test handy, please follow along.

Normal blood test ranges

  • This range is essentially the upper and lower limits within which most healthy people’s test results are expected to fall.
  • To determine how your test results compare with the normal range, you need to check the reference interval listed on your lab report.
  • If you have results for a given test from different labs, your clinician will likely focus on test trends relative to their reference intervals and not the numerical results themselves.

Interpreting your blood test results

  • There are numerous blood panels intended to test specific aspects of your health.
  • These include panels that look at the cellular components of your blood, biomarkers of kidney and liver function, and many more.
  • This results from either lower than normal levels of red blood cells or a decrease in the quantity or quality of hemoglobin, the protein that allows these cells to transport oxygen.
  • A complete blood count panel measures various components of the blood to provide a comprehensive overview of the cells that make it up.
  • Low values of red blood cell count, or RBC, hemoglobin, or Hb, and hematocrit, or HCT, would indicate that the patient is suffering from anemia.
  • Providing additional information is the basic metabolic panel, or BMP, which measures the amount various substances in your blood.


With results from each of these panels, the health professional would assess the patient’s values relative to their reference intervals and determine which condition they most likely have. Understanding the purpose of blood tests and how to interpret them can help patients partner with their health care providers and become more informed about their health.
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

iClick Interactive Asia Group Limited Reports 2023 Half-Year Unaudited Financial Results

Retrieved on: 
Wednesday, December 13, 2023
EBITDA, TSH, Entrepreneurship, Projection, Investment, Collection, Share repurchase, Net, Event Marketing Solutions, ADS, Accounting, Marketing, GAAP, Proxy, Improper integral, Table, Mergers and acquisitions, Bank, Insurance, Retail, Video game, Cryptocurrency, Holding company, Parent

Revenue from Enterprise Solutions was US$21.5 million for the first half of 2023, compared with US$29.5 million for the first half of 2022.

Key Points: 
  • Revenue from Enterprise Solutions was US$21.5 million for the first half of 2023, compared with US$29.5 million for the first half of 2022.
  • Gross profit margin decreased to 25.0% for the first half of 2023 from 29.5% for the first half of 2022.
  • Total operating expenses were US$40.7 million for the first half of 2023, compared with US$52.3 million for the first half of 2022.
  • Adjusted net loss for the first half of 2023 was US$21.7 million, compared with US$20.5 million in the first half of 2022.

iClick Interactive Asia Group Limited Enters into a Definitive Merger Agreement for Going-Private Transaction

Retrieved on: 
Friday, November 24, 2023
New Age, ADS, Marketing, Tripura Merger Agreement, Companies Act, Filter (signal processing), Harney Westwood & Riegels, Letter, Schedule, Ropes & Gray, Consortium, Proxy, Form 6-K, TSH, Class A share, Committee, The Company, AND, Support, Holding company, Security (finance), Cayman Islands, Limited, Mergers and acquisitions, Parent, Share (finance)

The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.

Key Points: 
  • The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its independent financial and legal advisors.
  • The Rollover Shareholders have agreed to vote all of the Shares beneficially owned by them in favor of the authorization and approval of the Merger Agreement and the Merger pursuant to the Support Agreement.
  • In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the "Schedule 13E-3").

EQS-News: Aareal Bank arranges refinancing of European portfolio for The Social Hub

Retrieved on: 
Thursday, December 14, 2023
The Social Hub, Security, Growth, White & Case, Plain Green Loans, Social, Arrangement, Henri de Pardieu, Student, Student's Hotel, CBRE, TSH, White, Pinsent Masons, Travel, Work, Aareal Bank, Rabobank, Tourism

Wiesbaden, 27 November 2023 – Aareal Bank announces the successful closing of a € 566 million refinancing facility with The Social Hub (TSH), together with two participating lenders, one of which being Rabobank.

Key Points: 
  • Wiesbaden, 27 November 2023 – Aareal Bank announces the successful closing of a € 566 million refinancing facility with The Social Hub (TSH), together with two participating lenders, one of which being Rabobank.
  • Operated under TSH’s hybrid hospitality concept offering co-working, events, hotel, extended-stay rooms and student accommodation, the cross-border portfolio comprises 13 properties across the Netherlands, Spain, France and the UK.
  • Aareal Bank acted as the Arranger, Agent, and Security Agent of the senior loan, which is classified by Aareal as a Green Loan under its own Green Finance Framework.
  • “We are delighted to establish this relationship with such a unique hospitality brand and operator as TSH,” comments Michelle Weiss, Head of Hotel Properties at Aareal Bank.

Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder

Retrieved on: 
Tuesday, November 7, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Trial of the century, IND, PD, MDD, Food, DSM-IV codes, CNS, MAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAD, Development, Pharmacokinetics, Autobahn, PK, Biology, Safety, Vital signs, Therapy, TSH, Central nervous system, Pharmaceutical industry, Vaccine

ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist, is an orally administered small molecule being evaluated as a potential adjunctive treatment for people with major depressive disorder (MDD).

Key Points: 
  • ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist, is an orally administered small molecule being evaluated as a potential adjunctive treatment for people with major depressive disorder (MDD).
  • Results from the Phase 1 study:
    Across the range of doses tested, ABX-002 was safe and well-tolerated.
  • There were no serious adverse events and no premature discontinuations related to safety, with all 48 subjects completing the study.
  • “The positive data from this Phase 1 study represent a major milestone for ABX-002 and support its advancement into Phase 2 development,” said Kevin Finney, President and Chief Executive Officer of Autobahn Therapeutics.

Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting

Retrieved on: 
Friday, September 29, 2023
Thyroid hormones, TSH, American Thyroid Association, Histology, Depression, FSE, ATA, FT4, Quality of life, PSH, Hypothyroidism, Weight gain, Thyroidectomy, Triiodothyronine, Patient, Cell, Annual general meeting, TSX, Poster, Memory, Fatigue, Thyroid, Medical imaging, Pharmaceutical industry

Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.

Key Points: 
  • Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.
  • Newly reported radio-isotope uptake imaging and histology assessments confirmed the presence of healthy and functional thyroid tissues within the Cell Pouch six months following re-implantation.
  • “With Sernova’s Cell Pouch System, we aim to improve quality of life with a treatment for post-operative hypothyroidism.
  • These new data replicate a human clinical scenario in which thyroid tissue is reimplanted into the patient, via the Cell Pouch, leading to the restoration of normal thyroid function.

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023
ENDO, TSH, Maintenance, KOL, Endocrinology, Carcinoid syndrome, Sequoyah, Glomus tumor, NDA, Congenital adrenal hyperplasia, Holocene, History, Octreotide, Graves' ophthalmopathy, Acromegaly, Entrepreneurship, Investment, PTH1R, SAN, PHPT, Primary hyperparathyroidism, Hospital, Research, FDA, Conference, Massachusetts General Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Congenital hyperinsulinism, Pharmaceutical industry, Cryptocurrency

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2023.
  • Enrollment in our Phase 3 PATHFNDR-2 study is also now complete and we anticipate topline results in the first quarter of 2024,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.
  • “Unfortunately, we also suffered a setback with our CRN04777 program and made the difficult decision to wind down its development.
  • PATHFNDR-1 is a placebo-controlled Phase 3 clinical study of oral paltusotine in participants with acromegaly switching from standard-of-care peptide depots.

Truvian Health Presents Multi-Site Clinical Study Data on Its Benchtop Blood Testing Platform to Enable Central Laboratory Quality Results Anywhere

Retrieved on: 
Tuesday, July 25, 2023
Research, Medical Devices, Medical Supplies, Clinical Trials, Health Technology, Cardiology, Biometrics, Biotechnology, Health, Science, TSH, Maintenance, AACC, Immunoassay, Patient, Blood, Hematology, Poster, Conditional sentence, Medical device

Truvian Health , a transformational and data-driven diagnostics company, today presented results from a recent multi-site clinical study at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting demonstrating the ability of its benchtop blood testing platform to deliver central laboratory quality results simultaneously across a large panel of assays.

Key Points: 
  • Truvian Health , a transformational and data-driven diagnostics company, today presented results from a recent multi-site clinical study at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting demonstrating the ability of its benchtop blood testing platform to deliver central laboratory quality results simultaneously across a large panel of assays.
  • Data presented include results of a multi-site method comparison study of 237 donor samples run on both Truvian’s platform and central laboratory analyzers.
  • Truvian’s platform showed excellent agreement to central laboratory analyzers in almost all assays in its panel.
  • Truvian’s Platform leverages three commonly used testing technologies – immunoassay, clinical chemistry, and hematology to simultaneously perform routine blood testing in minutes from a small sample of blood.